343 related articles for article (PubMed ID: 29447484)
21. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
22. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
[TBL] [Abstract][Full Text] [Related]
23. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
[TBL] [Abstract][Full Text] [Related]
24. Enhanced Influenza Immunity by Nasal Mucosal Administration of the TPGS-Modified Liposomal Vaccine.
Ma S; Yu R; Mai Y; Yu N; Gao T; Yang J
AAPS PharmSciTech; 2022 Sep; 23(7):272. PubMed ID: 36180652
[TBL] [Abstract][Full Text] [Related]
25. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection.
Lou G; Anderluzzi G; Schmidt ST; Woods S; Gallorini S; Brazzoli M; Giusti F; Ferlenghi I; Johnson RN; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
J Control Release; 2020 Sep; 325():370-379. PubMed ID: 32619745
[TBL] [Abstract][Full Text] [Related]
26. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models.
Ingvarsson PT; Rasmussen IS; Viaene M; Irlik PJ; Nielsen HM; Foged C
Eur J Pharm Biopharm; 2014 Aug; 87(3):480-8. PubMed ID: 24726978
[TBL] [Abstract][Full Text] [Related]
27. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.
Fan Y; Sahdev P; Ochyl LJ; Akerberg J; Moon JJ
J Control Release; 2015 Jun; 208():121-129. PubMed ID: 25869965
[TBL] [Abstract][Full Text] [Related]
28. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen.
Vangala A; Bramwell VW; McNeil S; Christensen D; Agger EM; Perrie Y
J Control Release; 2007 May; 119(1):102-10. PubMed ID: 17331610
[TBL] [Abstract][Full Text] [Related]
29. Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA.
Kallerup RS; Franzyk H; Schiøth ML; Justesen S; Martin-Bertelsen B; Rose F; Madsen CM; Christensen D; Korsholm KS; Yaghmur A; Foged C
Mol Pharm; 2017 Jul; 14(7):2294-2306. PubMed ID: 28497975
[TBL] [Abstract][Full Text] [Related]
30. Liposome-mediated DNA immunisation via the subcutaneous route.
Perrie Y; McNeil S; Vangala A
J Drug Target; 2003; 11(8-10):555-63. PubMed ID: 15203925
[TBL] [Abstract][Full Text] [Related]
31. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
[TBL] [Abstract][Full Text] [Related]
32. alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying.
Christensen D; Kirby D; Foged C; Agger EM; Andersen P; Perrie Y; Nielsen HM
Biochim Biophys Acta; 2008 May; 1778(5):1365-73. PubMed ID: 18261458
[TBL] [Abstract][Full Text] [Related]
33. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity.
Jiang PL; Lin HJ; Wang HW; Tsai WY; Lin SF; Chien MY; Liang PH; Huang YY; Liu DZ
Acta Biomater; 2015 Jan; 11():356-67. PubMed ID: 25242652
[TBL] [Abstract][Full Text] [Related]
34. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.
Hamborg M; Jorgensen L; Bojsen AR; Christensen D; Foged C
Pharm Res; 2013 Jan; 30(1):140-55. PubMed ID: 22956169
[TBL] [Abstract][Full Text] [Related]
35. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
[TBL] [Abstract][Full Text] [Related]
36. A liposomal vaccine promotes strong adaptive immune responses via dendritic cell activation in draining lymph nodes.
Agallou M; Margaroni M; Tsanaktsidou E; Badounas F; Kammona O; Kiparissides C; Karagouni E
J Control Release; 2023 Apr; 356():386-401. PubMed ID: 36893900
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
[TBL] [Abstract][Full Text] [Related]
39. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.
Gao J; Ochyl LJ; Yang E; Moon JJ
Int J Nanomedicine; 2017; 12():1251-1264. PubMed ID: 28243087
[TBL] [Abstract][Full Text] [Related]
40. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.
Henderson A; Propst K; Kedl R; Dow S
Vaccine; 2011 Jul; 29(32):5304-12. PubMed ID: 21600950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
